Kevin Rakin Appointed to the Histogenics Corporation Board of Directors

WALTHAM, Mass.--(BUSINESS WIRE)--Histogenics Corp., a biologics company that combines cell therapy and tissue engineering technologies to develop highly innovative products primarily for orthopaedic tissue repair and regeneration, today announced the appointment of Kevin L. Rakin to its Board of Directors. Mr. Rakin has over 20 years of experience in the biotechnology industry and most recently served as President of Regenerative Medicine at Shire plc. “We are very pleased to welcome Kevin to the Histogenics Board of Directors. His broad experience in biotechnology and regenerative medicine over a 20 year career will be extremely valuable during this exciting time for the company,” said Patrick O’Donnell, President and Chief Executive Officer of Histogenics. “We believe that Kevin’s experience with regenerative medicine treatments and understanding of niche markets will help us advance the clinical development program of NeoCart® and prepare it for commercialization."